Related Experiment Videos
Technetium-94m-teboroxime: synthesis, dosimetry and initial PET imaging studies
R J Nickles1, A D Nunn, C K Stone
1Department of Medical Physics, University of Wisconsin, Madison.
Summary
Technetium-94m (94mTc) enables in vivo study of radiopharmaceuticals using positron emission tomography (PET). This method offers quantitative biodistribution analysis for technetium agents in humans.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
- Positron Emission Tomography (PET) imaging
Background:
- Technetium-94m (94mTc) offers a suitable half-life for in vivo studies using PET.
- PET imaging provides high-resolution, quantitative biodistribution data for radiopharmaceuticals.
- Current methods for studying technetium agents in vivo are limited.
Purpose of the Study:
- To evaluate the potential of 94mTc for in vivo pharmacokinetic studies of technetium radiopharmaceuticals using PET.
- To assess the feasibility of using 94mTc-labeled teboroxime as a myocardial perfusion agent.
Main Methods:
- 94mTc was produced via proton irradiation of molybdenum and extracted electrochemically.
- 94mTc-pertechnetate was prepared for labeling teboroxime, similar to 99mTc-pertechnetate.
- Eleven clinical PET studies were conducted, comparing 94mTc-teboroxime with 13N-ammonia.
Main Results:
- The clearance half-time of 94mTc-teboroxime was approximately 8 minutes.
- Peak myocardial extraction of 94mTc-teboroxime was about 3% of the injected dose.
- Administered activity of 94mTc-teboroxime needed to be reduced sevenfold compared to 99mTc-teboroxime due to higher absorbed radiation dose.
Conclusions:
- 94mTc PET imaging is a viable tool for quantitative pharmacokinetic studies of technetium radiopharmaceuticals in humans.
- 94mTc-teboroxime demonstrates potential for myocardial perfusion imaging.
- This technique allows for detailed in vivo analysis of both new and existing technetium agents.